Post on 25-Aug-2020
[30] !""#$%&' (!)%'*%&' +#, $',#"!-+%&#, !(%,+#.#,
!"!#$%&'(% !")*+'*
!"#$%&'& "()*+,+-: ! "#$%#&'()* +,#-./)* ("+) 012#, 32# 45%26 %&62,7 264)µ# 875 4527(090/#, #86 47-#&3* 08,8:7$3*. ;87/0:01 /)2 $9&,# #,/1# <0:,$79 "/#(175 =&62,#* >0?&,$.* ;208@&$0,#* (<"=>;) 875 #8#,/01 #2/,µ0/'8,4) 01/0 µ0 #,µ7$@A#&4) (;B) 01/0 µ0 80&,/72#C$. $@A#&4) (DB). E %&72,6/)/# /)* 26475, #::@ $#, 7, 08,8/'40,* /)*, 08)&0-@F752 /7 G5%7:7H,$6, 7,$7H020,#$6 $#, $7,2I2,$6 80(17 $#, $#/J 083$/#4) /)2 D7,6/)/# KI.* (DK) /I2 #4A02'2. ./0123: E 0$/1µ)4) ?7&/175 26475 /I2 #4A02'2 µ0 +,#-)/,$. >0?&78@A0,# (+>) 8&7 /0:,$79 $#, /0:,$79 4/#(175. 45607080+9*: +01Hµ# /)* µ0:3/)* #87/3:04#2 103 #4A0201* µ0 +,#-)/,$. >0?&78@A0,# (+>) 875 #2/,µ0/I8,F6/#2 4/7 L02,$6 >747$7µ017 M3&7,#* $#/@ /75* µ.20* N@,7 $#, O792,7 2016. E 3&052# 8&#Hµ#/787,.A)$0 µ0 /) %&.4) /75 0&I/)µ#/7:7H175 Dialysis Symptoms Index (DSI) H,# /)2 0$/1µ)4) /75 ?7&/175 45µ8/Iµ@/I2 /)* =&62,#* >0?&,$.* >6475 (=>>). P814)* %&)4,µ787,.A)$0 /7 0&I/)µ#/7:6H,7 European Quality of Life (EuroQol) H,# /)2 0$/1µ)4) /)* DK #4A02'2 /75 >0?&7:7H,$79 PQI/0&,$79 O#/&0175, /)* N72@(#* <0%2)/79 >0?&79 $#, D0&,/72#C$.* B@A#&4)*. :10;58<)µ*;*: M&3A)$0 6/, ) µ3A7(7* 587$#/@4/#4)* 20?&,$.* :0,/75&H1#* (;B . DB), ) 8#&7541# "+, $#A'* $#, /7 4/@(,7 /)* =>> 08)&0@F752 40 4)µ#2/,$6 -#Aµ6 /)2 #5/7#Q,7:6H)4) /I2 #4A02'2 4/# 08'(52# 45µ8/'µ#/# /)* +>. P814)* 7, 8#@2I 8#&@H72/0* 08)&0@F752 4)µ#2/,$@ 8#&#µ3/&75* /)* DK /I2 #4A02'2 68I* $,2)/,$6/)/# $#, #5/70Q58)&3/)4). .=µ15>?)µ*;*: !, #4A0201* 8&7 /0:,$79 4/#(175 -,'2752 8,7 32/72# /# 08'(52# 45µ8/'µ#/# /)* +> 40 4%34) µ0 /75* #4A0201* /0:,$79 4/#(175.
%<@5(3 - A85(7(?: "#$%#&'()* +,#-./)*, R7&/17 >6475, D7,6/)/# KI.*, +,#-)/,$. >0?&78@A0,#, =&62,# >0?&,$. >647*
!"#$%& %&' "()*+,-&' %./ 0.+%)./ -/µ(%1µ2%13 -%&3 (.45%&%, 617' ,%5µ13 µ" 8"0+497 85-. (+.-
%"#49.: 9,4 %"#49.: -%,*)./
!,-./ )0123456781, 9076:2; (;8<452, !830.=; >/.;?=6783, (8245<7@ (;A5<7@4, *,0B5.62; C/µ/D2456785
1. $7?/,0ED24;, MSc, )0.4<F $7?7<7µ0=7 %µ;G=;@->7.56; H-274;@2. (;G/3ID24; !J;2µ73:., &µIµ; $7?/,08D4<I@, *,0B5.62047 &0K.7,734<F !<L;4608D4<F M628µ; 90??;,7.=</@3. !L=<782/ (;G/3ID24;, &µIµ; $7?/,08D4<I@, *,0B5.62047 &0K.7,734<F !<L;4608D4<F M628µ; 90??;,7.=</@
4. *.;L,/21DI@/D24; (;G/3/DI@/D24;, &µIµ; $7?/,08D4<I@, *,0B5.62047 &0K.7,734<F !<L;4608D4<F M628µ; 90??;,7.=</@
#L0EG8./ ;,,/,732;J=;@: 9076:2; (;8<45&µIµ; $7?/,08D4<I@*&!' 90??;,7.=</@&9 14157400 +=.67@, 90??;,7.=</e-mail: dkafkia@hotmail.com
%µ027µ/.=; 8L7N7,I@: 10/05/2017%µ027µ/.=; C/µ7?=08?/@: 107@ 2017
2017, 10(3): 30-42
!"#"$ 10 - !%&'"$ 3 [31]
!"!#$%&'(% !")*+'*
, !"#$"%&'() *+",-.() (!*) #"+ ( /%01+" 234%+-#- 2056) (/22) 371"+ '86 $%01+" 165-µ"." 96: 5:1';61."+ 5.31< µ3."=8 .6:) #"+ "9"+.681 .(1
9%656$- .() 9">#05µ+") +".%+#-) #"+ 165(?3:.+#-) #6+-10.(."). @:.0 5:µ,"713+ ?0>A .6: ":="10µ316: 39+96-?"5µ68, .A1 39+9?6#&1 96: 9"%6:5+<B61."+, .6: ":=(-µ;16: 6+#616µ+#68 #05.6:) >+" .(1 "1.+µ3.&9+5- .6:), .() "1<>#() 5:$1&1 165(?3+&1 #"+ 9"%6$-) :9(%35+&1 :>37") #"+ #".< 5:1;93+" .() C6+0.(.") DA-) (CD) .A1 5:>#3#%+µ;1A1 6µ<'A1 "5E31&1.
C">#65µ7A), 6 "%+Eµ0) .A1 ".0µA1 96: 9<5$6:1 "90 !* "1;%$3."+ 93%796: 5." 415 3#".6µµ8%+", "%+E-µ0) 96: "1"µ;13."+ 1" 4.<53+ ." 642 3#".6µµ8%+" ;A) .6 2040.@:.0 5(µ"713+ 0.+ ;1") 5.6:) ;1.3#" 31-?+#3) ;$3+ !*, "1"?6>7" 96: .6 2040 E" 371"+ ;1") 9%6) ';#". F1" 39+9?;61 "1(5:$(.+#0 5.6+$376 371"+ 0.+ ;1") 5.6:) '86 31-?+#3) '+",(.+#68) 1" 9"%"µ;13+ "'+<>1A5.6), µ3 "96.;?35µ" .(1 "8=(5( #+1'816: 3µ4<1+5() 39+9?6#&1 #"+ 5:139&) "8=(5( .6: #05.6:) "1.+µ3.&9+5-) .6:) (IDF 2015).
C"%<??(?", ( /22 "1">1A%7B3."+ "90 .61 C">#05µ+6 G%>"1+5µ0 H>37") A) B-.(µ" '(µ05+") :>37") '+3E1&). !.(1 I??<'", .6 10% .6: 9?(E:5µ68, '(?"'- 93%796: 1 3#".6µµ8%+6 <1E%A96+ 9<5$6:1 "90 /22. J<?+5." 5.(1 390µ31( '3#"3.7" .6 96565.0 ":.0 "1"µ;13."+ 1" ":=(E37 5.6 17%. I71"+ ;1" 5(µ"1.+#0 9%0,?(µ" :>37"), 96: $"%"#.(%7B3."+ "90 ;??3+K( 5:µ9.Aµ<.A1 #".< ." "%$+#< 5.<'+", ;.5+ µ96%37 #<96+6) 1" ;$3+ ;#9.A5( .() 134%+#-) ?3+.6:%>7") #"+ 1" µ(1 .6 >1A%7B3+(L"?6>3%<) 2015). M *+",(.+#- 234%69<E3+" (*2), A) "90.6#6) µ+") 3# .A1 µ+#%6">>3+"#&1 39+9?6#&1 .6: !*, 3µ4"17B3."+ 53 96565.0 20-40% .A1 "5E31&1 #"+ "96.3?37 .(1 #8%+" "+.7" N3?+#68 !."'76: /22 (ADA 2011).
J3 ,<5( ." 9"%"9<1A >713."+ "1.+?(9.0 0.+ ( 89"%=( 310) $%01+6: 165-µ".6) 39+4;%3+ "??">;) 53 0?6:) .6:) .6µ37) ;#4%"5() 310) ".0µ6: #"+ 39(%3<B3+ 5(µ"1.+#< .(1 CD .6: (C6?:#"1'%+&.( #"+ 5:1 2005). G+ 39+9.&53+) µ7") $%01+") 1056:5.(1 #"E(µ3%+10.(." .6: ".0µ6:, 37-1"+ 5:1<%.(5( .() ,"%8.(.") .() 1056:, .6: .%096: µ3 .61 69676 #<E3 <.6µ6 "1.+µ3.A97B3+ .( 1;" #".<5."5( #"+ .A1 :965.(%+#.+#&1 '6µ&1/':1".6.-.A1 96: :9<%-
$6:1 5.( BA- .6:. M /22 3="+.7") .() 56,"%0.(.<) .() #"+ .A1 "9"+.-53A1 96: :9<%$6:1 5.(1 "1.+µ3.&9+5- .() µ3 @+µ6#<E"%5( (@L) - C3%+.61"O#- L<E"%5( (CL), 4"713."+ 0.+ 39(%3<B3+ 53 '+"46%3.+#0 ,"Eµ0 .6 5816?6 .A1 9.:$&1 96: 5:1E;.6:1 .( BA- 310) ".0µ6: (Cavalli et al 2010).
J3?;.3) ;$6:1 '37=3+ 0.+ ( C6+0.(." DA-) (CD) ".0-µA1 96: :96,<??61."+ 53 "+µ6#<E"%5( 39(%3<B3."+ "90 ;1" 5816?6 9"%">01.A1 96: 5$3.7B61."+ µ3 .( 1056 ":.- #"E3":.-, "??< #"+ µ3 '+<46%6:) <??6:) 9"%<>6-1.3), 09A) (?+#7", 48?6, µ6%4A.+#0 #"+ 6+#616µ+#0 397-93'6 #"+ 5:165(%0.(." (P3647?6: & C"1">+A.<#( 2010, P3647?6: 2011). @1.7E3.", 6+ "5E3137) 96: :96,<??61."+ 53 93%+.61"O#- #<E"%5( ;$6:1 µ3>"?8.3%( "13="%.(57" #"+, >31+#0.3%", #"?8.3%( 9%65"%µ6>- 5.( 1056 #"+ .( E3%"937" (Wu et al 2004). M 3#.7µ(5( .() CD E3A%37-."+ "90 .6:) 3%3:1(.;) "9"%"7.(.( >+" 1" #"E6%+5.37 ( "96.3?35µ".+#0.(." .() 9"%3$0µ31() :>3+616µ+#-) 4%61.7'"), ( 9%65"%µ6>- 5.( 1;" 9%">µ".+#0.(." µ3 .( 1056 #"+ 6 ,"Eµ0) .() ":.64%61.7'") (Unruh et al 2005, Kourakos 2017). !#690) .() 9"%685") µ3?;.() -."1 ( 3#.7µ(5( .6: 46%.76: 5:µ9.Aµ<.A1 1056: 53 "5E3137) µ3 *2 9%6-.3?+#68 #"+ .3?+#68 5."'76: 96: :96,<??6-1."+ 53 "+µ6#<E"%5( #"+ 93%+.61"O#- #<E"%5(, #"+ 9A) 39(%3<B3+ .(1 96+0.(." BA-) .6:).
!"#$%$&$'()*+,-./0µ12 3/. 0455678 -,-6µ9:;:
J+" 5:>#%+.+#- µ3?;.( $%61+#-) 5.+>µ-) 9%">µ".6-96+-E(#35.6 Q31+#0 2656#6µ376 R;%6+"), #"+ 5:>#3-#%+µ;1" 5.6 234%6?6>+#0 I=A.3%+#0 S".%376 (2IS), .( J61<'" N3$1(.68 234%68 #"+ C3%+.61"O#-) L<E"%5(). C%653>>75.(#3 .6 5816?6 .A1 "5E31&1 µ3 36 #"+ 465.<-'+6 /22,96: 9"%"#6?6:E681."+, 53 ."#.+#0 %"1.3,68, 5.6 3=A.3%+#0 134%6?6>+#0 +".%376 (n=50), .6 5816?6 .A1 ".0µA1 53 @L (n=80) #"+ CL (n=20) .6: 1656#6µ37-6:.
L%+.-%+" "96#?3+5µ68 "90 .( µ3?;.( "96.;?35"1 ( µ( 39"%#-) >1&5( .() I??(1+#-) >?&55"), ( #&4A5( - .84?A5(, #"E&) #"+ ( <16+". @96#?375.(#"1, 3975(), "5E3137) µ3 G=37" 234%+#- @139<%#3+" (G2@) #"+ 056+
<)*(=A *>!"?)
-./ 0123/4/ 1-0 35467/0 17µ5-4µ0-0 -89 :;0<8-;=>9 $3?@A5B23;09
-./ 0123/4/
C.>9 -./ 0123/4/ =0; =7@D.9 -A79 -Aµ3D9 -89 =;/8-;=E-8-09 =0; 07-A3F758@G-8189.
[32] !""#$%&' (!)%'*%&' +#, $',#"!-+%&#, !(%,+#.#,
!"!#$%&'(% !")*+'*
!"#$ %&"' "'$ 18 (")$ ! *( +(,#-(.# /0# 1,2$0%3 40&-*"5µ# µ0%,3"(,2 "'$ 6 µ5$)$. 6("& #-3 ($5µ7,'*5, 43+5%( 5 -85,292,5µ7$5 *:/%#"&+(*5 #-3 103 #*+(-$(.; (response rate 68,7%). <# 4(42µ7$# *:8871+5%#$ µ( *:$7$"(:=5 -2: 40#,%2>*( -(,.-2: 25 8(-"& *"5 40-&,%(0# "5; *:$(4,.#; #0µ2%&+#,*5; ! "2: -,2/,#µµ#"0-*µ7$2: ,#$"(?2> /0# 78(/12 *"2 @AB ! "5 µ2$&4# -(,0"2-$#C%!; %&+#,*5;.
!"#$µ% µ"&'()*<2 4(./µ# "5; µ(87"5; #-2"78(*#$ 103 #*+($(.; "2:
D($0%2> @2*2%2µ(.2: E7,20#;, %#0 *:/%(%,0µ7$# 37 #*+($(.; "2: @(9,282/0%2> A='"(,0%2> B#",(.2:, 46 #*+($(.;"5; 62$&4#; <(1$5"2> @(9,2> %#0 20 "5; 62-$&4# F(,0"2$#C%!; G&+#,*5;.
+,$%&"#% µ'(,)-)*H"5$ -#,2>*# µ(87"5 "# (,/#8(.# µ7",5*5; -2: 1,5-
*0µ2-20!+5%#$ !"#$ 5 A:,'-#C%! G8.µ#%# F203"5"#; I'!; (European Quality of Lifescale, EuroQoL) %#0 2 J(.%"5; H:µ-"'µ&"'$ G&+#,*5; (Dialysis Symptoms Index, DSI).
<2 EuroQoL, %#0 5 $()"(,5 µ2,9! "2: EuroQoL -5 Dimensions - 3 Levels (EuroQoL-5D-3L) (Rosetetal 2001), (.$#0 7$# #:"2*:µ-85,2>µ($2 (,/#8(.2 /0# "5$ µ7",5*5 "5; -203"5"#; K'!; "2 2-2.2 71(0 1,5*0µ2-20-5+(. (:,>"#"#. L1(0 µ("#9,#*"(., *"#+µ0*"(. %#0 1,5*0-µ2-205+(. *"2$ A885$0%3 -85+:*µ3 (Yfantopoulos 1998, Yfantopoulos 2001).M-2"(8(."#0 #-3 4>2 µ7,5, "2 -,)"2 %#"#/,&9(0 "2 -,29.8 :/(.#; "2: #"3µ2: *( -7$"( 40#-*"&*(0; -2: *:µ?&882:$ *"5$ #=0283/5*5 "5; FI (%0$5-"0%3"5"#, #:"2(=:-5,7"5*5, *:$!+(0; 4,#*"5,03"5"(;, -3$2/4:*92,.# %#0 &/12;/+8.N5), %#0 "2 4(>"(,2, µ0# O-"0%! M$#82/0%! G8.µ#%# µ( "5 µ2,9! +(,µ3µ(",2: :/(.#;, %#"#/,&9(0 "5$ :-2%(0µ($0%! (%".µ5*5 "2: #"3-µ2: /0# "5$ -#,2>*# %#"&*"#*5 :/(.#; "2: (P9#$"3-2:-82; 2007).
Q; 4(>"(,2 (,/#8(.2 7,(:$#; 1,5*0µ2-20!+5%( "2DSI -2: #=0282/(. "5 *:1$3"5"# (µ9&$0*5; µ0# -20%0-8.#; *'µ#"0%)$ %#0 N:10%)$ *:µ-"'µ&"'$ "5; R@@ (Weisbord et al 2004, Murtagh et al 2007, Almutaray et al 2013).
.'µ%(% /0123*-!"45(4&4$#%*S *:882/! "'$ 4(42µ7$'$ -,#/µ#"2-20!+5%( µ("&
#-3 7/%,0*5 "5; A-0*"5µ2$0%!; A-0",2-!; %#0 "2: J020-%5"0%2> H:µ?2:8.2: "2: D($0%2> @2*2%2µ(.2: Sµ#+.#; – 62$&4# E7,20#; %#0 "5; A-0",2-!; S+0%!; %#0 J(2-$"282/.#; "5; P/(02$2µ0%!; F(,097,(0#; (PFA). O0 #,-17; "5; J0#%!,:=5; "2: Helsinki /0# "# 40%#0)µ#"# "'$ #*+($)$ "5,!+5%#$ -8!,'; %#"& "5 40(=#/'/! "5; µ(-87"5;. 63$2 "# #,10%& "2: 2$3µ#"2; "'$ *:µµ("(13$"'$ %#"#/,&92$"#$ %#0 "# (,'"5µ#"283/0# *:µ-85,)$2$"#$
,-./0/1 1. 23µ456/7809 :/6/0;368<;809 ;4= >?-5µ/;41
n/N %
67&4
T$4,(; 66/103 64.1
D:$#.%(; 37/103 35.9
8124$"5"1%23 2%(9-(%-)
T/#µ2; 5/103 4.9
L//#µ2; 81/103 78.6
J0#K(:/µ7$2; 2/103 1.9
R!,2; 15/103 14.6
+2:%#;"<-)
65 282%8!,'*5 J5µ2"0%2> 25/103 24.3
M-3920"2; J5µ2"0%2> 48/103 46.6
M-3920"2; D:µ$#*.2: 14/103 13.6
M-3920"2; U:%(.2: 6/103 5.8
M-3920"2; B.A.G 1/103 1.0
F":102>12; <.A.B 3/103 2.9
F":102>12; F#$(-0*"5µ.2: 6/103 5.8
G&"212; 6("#-":10#%2> 0/103 0
+:9$$"&µ%
O0%0#%& 7/103 6.8
T$(,/2; 6/103 5.8
J5µ3*02; P-&88582; 3/103 2.9
B40'"0%3; P-&88582; 2/103 1.9
A8(>+(,2; A-#//(8µ#".#; 2/103 1.9
H:$"#=02>12; 83/103 80.6
=>:4* ?%(412#%*
M*"0%! -(,021! 48/103 46.6
M/,2"0%! -(,021! 55/103 53.4
@'-) =1µ3 =.A (95% !.+)
/&12#% 68.5 7"5 ±12.2 (95% JA: 66.1-70.9)
µ("& #-3 -85,292,5µ7$5 *:/%#"&+(*5.
B(%(1-(123 A59&<-)S *"#"0*"0%! (-(=(,/#*.# "'$ #-2"(8(*µ&"'$ 7/0$(
µ( "2 *"#"0*"0%3 -,3/,#µµ# IBM SPSS Statistics v20. H"5$ -(,0/,#90%! *"#"0*"0%! 20 *:$(1(.; µ("#?85"7; -2: (.1#$ %#$2$0%! %#"#$2µ! (%9,&*"5%#$ µ( "5 µ7*5 "0µ! (mean), "5$ ":-0%! #-3%80*5 (SD) %#0 "# 95% J0#*"!µ#"# Aµ-0*"2*>$5; (95%JA), ($) 20 µ("#?85"7; 20 2-2.(; 4($ (.1#$ %#$2$0%! %#"#$2µ! (%9,&*"5%#$ µ( "5 40&µ(*2
!"#"$ 10 - !%&'"$ 3 [33]
!"!#$%&'(% !")*+'*
(median) !"# $% &'(%) $#µ*+ (range). ,# -#./$%µ&) !"# !"$01%(#!2) µ&$"340$2) &!5(67$0!"+ µ& 78.+/$0$&).
9$0+ "+"48$#!: 7$"$#7$#!: 1#" $#) 78+&.&;) µ&$"340-$2) %# %<%;&) -&+ &;."+ !"+%+#!: !"$"+%µ: .(07#µ%<%#:-=0!"+ %# µ0 <"("µ&$(#!2) -%!#µ"7;&) Mann-Whitney U Test !"# Kruskal-Wallis Test 1#" $0 7'1!(#70 $>+ µ27>+ µ&$"?' "+&?6($0$>+ -µ6$>+. @#" $%+ 24&1.% $%8 3"=-µ%' 787.2$#70) µ&$"?' -'% 78+&.*+ µ&$"340$*+ <%8 -&+ &;."+ !"+%+#!: !"$"+%µ: .(07#µ%<%#:=0!& % 78+$&-4&7$:) 787.2$#70) Spearman’ s rhocorrelation. , 24&1-.%) $>+ -#./$%µ>+ !"# !"$01%(#!*+ µ&$"340$*+ µ&$"?' -'% "+&?6($0$>+ -µ6$>+ 21#+& µ& $0 7$"$#7$#!: -%!#-µ"7;" Chi-square test !"# Fisher’ s exact test. , 24&1.%) /4>+ $>+ 8<%=27&>+ 21#+& 1#" &<;<&-% 7$"$#7$#!:) 70-µ"+$#!/$0$") p<0.05.
!"#$%&%'(!$!)*+*,-.+/0-/,1 2345µ*-67
A% -&;1µ" $0) <"(%'7") µ&42$0) &;.& µ270 04#-!;" 68.5(±12.2) 2$0, "<%$&4%'+$"+ !8(;>) "</ 6+-(&) (64.1%, n=66), 211"µ" 6$%µ" (78.6%, n=81), "</5%#$%8) <(>$%36=µ#") &!<";-&870) (46.6%, n=48) !"# !"$6 78-+$(#<$#!: <4&#%B05;" 78+$"?#%'.%8) (80.6%, n=44). C;1% <&(#77/$&(%# "</ $%8) µ#7%') (53.4%, n=55) !"$%#!%'-7"+ 7& "1(%$#!: <&(#%.:, &+* %# 8</4%#<%# 7& "7$#!: (D;+"!") 1).
E</ $%8) 78µµ&$2.%+$&) 7$0 µ&42$0 $% 44.7% (n=44) 8<%3"44/$"+ 7& "#µ%!6="(70 !"$6 µ27% /(% 5,5(±4,9) 2$0, $% 21.4% (n=22) 7& <&(#$%+"F!: !6="(70 1#" 3,9(±2,6) 2$0 !"# $% 35.9% (n=37) <"("!%4%8=%'+$"+ 7$% GHI µ& 3% !"# 4% 7$6-#% JGG1#" 5,5(±3,6) 2$0, &+* 0 G&5(#!: G/-7%) &;.& -#"1+>7$&; 1#" <(*$0 5%(6 7,8(±11,7) 2$0 <(#+ $0+ 2+"(?0 K&("<&;") L<%!"$67$"70) $0) G&5(#!:) C&#$%8(1;") (KLGC).E+"5%(#!6 µ& $0+ '<"(?0 78+%-*+ +%70µ6$>+ 4;1% <&(#77/$&(%# "</ $%8) µ#7%') "7=&+&;) (53/103) &;."+ 9M !"$6 µ27% /(% 1#" 17,8(±10,2) 2$0. N !"$"+%µ: $>+ -#"30$#!*+ "+6 µ2=%-% 8<%!"$67$"-70) $0) +&5(#!:) 4&#$%8(1;") <"(%87#6O&$"# 7$% 9.:µ" 1. H<;70), <&(;<%8 $" $(;" $2$"($"$>+ 78µµ&$&./+$>+ (72,8%, n=75) "+25&("+ /$# &;."+ E($0(#"!: L<2($"70, $% 2+" $(;$% "11&#%<6=&#" (36/103) !"# 7.&-/+ 2?0 7$%8) -2!" "+"#µ;" (n=59).A24%), "+"5%(#!6 µ& $#) &<#<4%!2) "</ $% 9M, 4;1% <&(#77/$&(%# "</ $%8) µ#7%') (29/53) "+25&("+ <(%34:µ"$" 7$0+ /("70, %# µ#7%; (26/53) <&-(#5&(&#"!: "11&#%<6=&#", $% 2+" $2$"($% /$# &;.& <&(67&# ,?' Pµ5("1µ" Q8%!"(-;%8 (,HQ) !"# $% 2+" 2!$% E11&#-"!/ H1!&5"4#!/ H</-#% (EHH).
R"$6 $0 -#"-#!"7;" "8$%"?#%4/1070) $0) !"$67$"-70) 81&;"), %# "7=&+&;) "+"52(%8+ !6<%#" <(%34:µ"$" !#+0$#!/$0$") (61,2%, n=63), µ2$(#%8) </+%8) : -875%-(;" (49,5%, n=51) !"# µ2$(#% 61.%) : =4;B0 (53,4%, n=55), "446, <"(/4" "8$6, /$# &;+"# 7& =270 +" "8$%&?8<0(&-
,-./01µµ1 1. 231045 +16710895 ,-1:;<5 1=. >?@A9A #3A61<.B<1B5C $DE0-6;C FD-<AG0/H1C
[34] !""#$%&' (!)%'*%&' +#, $',#"!-+%&#, !(%,+#.#,
!"!#$%&'(% !")*+'*
!"#$%& (73,8%, n=76) '() *!) +,& (&!)µ,!-./0$1& '(&2&( .3*45"µ( 6!)7 '(#"µ,3)&27 !$17 +3(6!"3)*!"!,7 (53,4%, n=55) (8/&('(7 2).
9!$& ./&('( µ.$3,/ &( .(3(!"3:6,) '(&,/7 *!) !*6$ $) +)(4"!)'$/ *6$ '() $) µ" +)(4"!)'$/ (6#,&,/7 (&!)µ,-!-./0$1& µ,3)'; .3$45:µ(!(, (55; #,-3$%& *!) ,/&() (1!$,<1."3,!$%µ,&$) (41,2%,n=32 '() 57,9%,n=44, (&!/-6!$)=(). > +)(?$3; (&;µ,6( 6!)7 +%$ $µ;+,7 ,&!$./0,!() 6!" +1&(!*!"!( ,'!25,6"7 !-& '(#"µ,3)&@& +3(6!"3)$-!:!-&, *.$1 $) +)(4"!)'$/ (6#,&,/7 .$1 +,& (&!)µ,!-./-0$1& '(&2&( .3*45"µ( ,/&() (3',!; 5)A*!,3$) (.* !$17 µ" +)(4"!)'$%7 (61,8%,n=21 6, 6=26" µ, !$ 38,2%,n=34). B./6"7, $ /+)$7 (3)#µ*7 +)(4"!)'@& (6#,&@& (n=21, 61,8%) (&(?23,) *!) (&!)µ,!-./0,) ';.$)( .3$45:µ(!( '(!; !"& ,.)!25,6" !-& '(#"µ,3)&@& !$1 +3(6!"3)$!:-!-& 6, (&!/#,6" µ, !$17 µ"-+)(4"!)'$%7 (38,2%, n=13) .$1 +,& (&(?23$1& ';.$)( .3$45:µ(!(. 8(3(!"3,/!() µ)( ,.).52$& $µ$)*!"!( +)(4"!)'@& '() µ" +)(4"!)'@& (6#,&@& 6!" +);6!(6" .$1 (?$3; !$ ;A=$7/#5/C". 8)$ (&(51!)';, " .5,)$C"?/( !*6$ !-& +)(4"!)'@& (54,5%, n=30) *6$ '() !-& µ" +)(4"!)'@& (6#,&@& (45,5%, n=25) 4)@&$1& µ2!3)$ ;A=$7. D25$7, $) µ"-+)(4"!)'$/ (6#,&,/7 6, .$6$6!* 54,4% (n=25) (&(?23$1& (.$16/( .*&$1, ,&@ (&!/#,!( " .5,)$C"?/( !-& +)(4"!)'@& (6#,&@& (52,9%, n=27) 4)@&,) µ2!3)$ .*&$. E5$'5"3@&$&!(7 !"&
(&;516" !$1 EuroQoL-5D-3L, $) 61µµ,!2=$&!,7 6!"& $.!)': (&(5$A)': '5/µ('( 6"µ,/-6(&, '(!; µ26$ *3$, 61,99(±17,2) ,'(!$6!;, *.$1 100 " '(5%!,3" '(!;6!(6" !"7 1A,/(7 '() 0 " =,)3*!,3".
D25$7, 6!$ +,%!,3$ ,3A(5,/$ µ2!3"6"7 (DSI) 432#"-', *!) $) (6#,&,/7 ,'+"5@&$1& '(!; µ26$ *3$ 13,7(±6,4) 61µ.!@µ(!( µ, ,%3$7 (.* 2&( 2-7 !3);&!( +%$. F&(51-!)'*!,3(, $) (6#,&,/7 6, 8G 4)@&$1& 17,4 ((.* 4 -7 32) 61µ.!@µ(!(, $) ()µ$'(#()3*µ,&$) 11,06 ((.* 1 -7 28) '() $) HBI 15,6 ((.* 7 -7 27) 61µ.!@µ(!(. > 61=&*!"!( ,µ?;&)6"7 !-& 61µ.!-µ;!-& .(3$16);0,!() 6!$& ./&(-'( 3.
!"#$%&'()* +,-./#+ µ( 01 µ23/4/ +,0)µ(056)'1* ,(-7%)$8* ,9'/"
91A'3/&$&!(7 !( 61µ.!@µ(!( !"7 JHH, .$1 (&(?2-3$1& $) (6#,&,/7,(&;5$A( µ, !" µ2#$+$ (&!)µ,!@.)6"7 !"7 &*6$1 (FG, 8G : HBI), 432#"', *!) $) µ)6$/ .,3)!$&(-K'$/ (6#,&,/7 ,µ?(&/0$1& 2µ,!$ (p=0,034) '() !3,)7 6!$17 +2'( '(!;#5)C" (p=0,036). L%$ 6!$17 +2'( (6#,&,/7 6, ()µ$';#(36",'+"5@&$1& (&"61=/( (p=0,022), 2&( !3/-!$ 5%." (p=0,023) '() ,.!; 6!$17 +2'( (&"61=/(-;A=$7 (p=0,043). M55( 61µ.!@µ(!( .$1 (&(?23$&!() (.* .,-3)66*!,3$ (.* !( !3/( .2µ.!( !-& ()µ$'(#()3*µ,&-& ,/&() " (+)(?$3/( A)( 6,< (p=0,003), " +16'$5/( 6!( 6,-
,-./0/1 2. *234/5647896:; /:<=.>. 96/ 3;. 0/3?:3/:; 3;1 29=-/1 3421
!: ;1-!: !<,/./
=),10)$9010+ J-3/7 .3*45"µ( 13 24 35,9%(n=37)
N,3)'; .3$45:µ(!( 38 25 61,2%(n=63)
E5)': (&)'(&*!"!( 2 1 2,9%(n=3)
>"0/(?"61%201'1 J-3/7 .3*45"µ( 32 44 73,8%(n=76)
N,3)'; .3$45:µ(!( 11 3 13,6%(n=14)
E5)': (&)'(&*!"!( 10 3 12,6%(n=13)
=+31µ(%),2* 4%+'01%)9010(* J-3/7 .3*45"µ( 21 34 53,4%(n=55)
N,3)'; .3$45:µ(!( 21 13 33% (n=34)
E5)': (&)'(&*!"!( 11 3 13,6% (n=14)
@9,/* F.$16/( 21 25 44,7% (n=46)
N2!3)$7 27 24 49,5% (n=51)
O.,34$5)'*7 4 2 5,8% (n=6)
A#B/* F.$16/( 10 17 26,2% (n=27)
N2!3)$ 30 25 53,4% (n=55)
O.,34$5)'*7 13 8 20,4% (n=21)
=.&µ+$+ +"0/+?)/.9#1'1* "#(&+*
;2'1 C)µ8 C.> (95% :.D)
61,9 ±17,2 (95% LB: 58,6-65,3)
!"#"$ 10 - !%&'"$ 3 [35]
!"!#$%&'(% !")*+'*
,-./0/1 3. 2345-3 .6738.
+89.65:5/ ;0<=>?7:1 78µ@5Aµ/531 %
!"#$%&'&( 1 !"#$ %& µ'#(
)"**'+ !"#'+ %& µ'#(
1 !"#$ %&, -./"µ$/(
1 !"#$ %" µ0,(
)"**'+ !"#'+ %&, -./"µ$/(
)"**'+ !"#'+ %" µ0,(
!"µ)&*µ(&(
1234"5*56%&%( 61/103 13,6 1,0 11,7 11,7 15,5 5,8
7(2%8( 32/103 1,9 1,9 10,7 4,9 7,8 6,8
9µ-%"+ 21/103 1,0 1,0 5,8 1,9 8,7 1,9
15$##"5( 19/103 1,9 0 1,9 1,0 11,7 1,9
:-5;µ',& 6#-<& 34/103 1,0 2,9 6,8 7,8 5,8 8,7
:2=4'+ 4#$µ>-+ 58/103 10,7 2,9 6,8 13,6 18,4 3,9
?8/&µ( 4$%; $4#;, 36/103 5,8 5,8 5,8 9,7 5,8 1,9
1234"*8( 3%&, (,(>,"0 57/103 7,8 13,6 5,8 17,5 3,9 6,8
@(*$/( 43/103 5,8 2,9 8,7 8,7 8,7 6,8
AB,/#"µ" C,032D;, >"/5E, 15/103 1,9 1,0 4,9 1,0 3,9 1,9
:"B/5(3µ( >"/5E, 39/103 2,9 6,8 3,9 10,7 6,8 6,8
F6>;3& 73/103 10,7 17,5 5,8 22,3 4,9 9,7
G0D(+ 42/103 7,8 2,9 1,9 13,6 7,8 6,8
H&#"3%"µ8( 56/103 13,6 11,7 3,9 13,6 7,8 3,9
)6,"+ 3%5+ (#I#E3-5+ 0 %( "3%$ 58/103 7,8 11,7 4,9 18,4 8,7 4,9
)6,"+ 3%" IE#(4( 20/103 1,0 0 3,9 3,9 9,7 1,0
)","4'!(*"+ 46/103 1,0 1,9 9,7 8,7 20,4 2,9
:2=4"8 >6,"5 29/103 1,9 0 4,9 7,8 7,8 5,8
1234"*8( 32J4',%. 37/103 1,0 3,9 2,9 9,7 8,7 9,7
H&#"/-#µ8( 29/103 4,9 2,9 3,9 9,7 1,9 4,9
K(J"B#( 38/103 2,9 4,9 6,8 12,6 4,9 4,9
C,&32D8( 36/103 4,9 4,9 2,9 11,7 7,8 2,9
7-2#546%&%( 36/103 3,9 6,8 2,9 11,7 6,8 2,9
CL>,8( 50/103 11,7 2,9 1,9 22,3 4,9 4,9
1B34"*"+/C,032D"+ B>,"+ 48/103 9,7 2,9 1,9 20,4 5,8 5,8
M2-#-I53%6%&%( 32/103 1,9 2,9 1,9 14,6 7,8 1,9
NB>& 53/103 3,9 8,7 4,9 15,5 12,6 5,8
C,&32D8( / OJD"+ 78/103 5,8 9,7 9,7 23,3 19,4 7,8
F(%$I*5P& 22/103 1,0 3,9 1,0 7,8 3,9 3,9
C/5(!"#8( J5( sex 79/103 1,0 30,1 0 7,8 23,3 14,6
1234"*8( 3%( 3-<"2(*54$-#-I83µ(%( 80/103 1,9 33,0 0 9,7 14,6 18,5
724%"2#8( 55/103 17,5 24,3 2,9 5,8 2,9 0
[36] !""#$%&' (!)%'*%&' +#, $',#"!-+%&#, !(%,+#.#,
!"!#$%&'(% !")*+'*,
-./0
/1 4
. +2
3045
67 2
8/49
71 +
/0:/
4;<7
=5/
>?@7
0/5
A-<
BC1
DA4/
8A-/
1 .A
E45
0?1
.F6B
C µA
@7.
0/@G
6@/6
7 @7
1 C3
A-/1
@H.
/6DA
.;.
!"#
$#"
%&'
()*
+"
4 18
,2%
26
56,5
%
8
21,6
%
13
24
,5%
+$&
,!"
%&'
()*
+"-
"
16
72
,7%
p=
0,0
35
19
41,3
%
p= 0
,000
29
78
,4%
p=
0,0
16
38
71,7
%
p= 0
,026
'),!
* "
#,!
"#'-
*-"
2 9,
1%
1
2,2%
0 0,
0%
2
3,8%
".
-'$/
.%*
&$-*
0*
!
"#$%
&'()
*+
($,
&*(-
(#.+
"/. $
(%#"
$&
..0
N
% p
# %
p #
% p
# %
p
!"#
$#"
%&'
()*
+"
14
63
,6%
37
80,4
%
27
73
,0%
32
60,4
%
+$&
,!"
%&'
()*
+"-
"
2 9,
1%
p= 0
,086
6
13,0
%
p= 0
,242
6
16,2
%
p= 0
,842
11
20
,8%
p=
0,0
05
'),!
* "
#,!
"#'-
*-"
6 27
,3%
3 6,
5%
4
10,8
%
10
18
,9%
$!
-$)$
0* 0
.#*
1,0+
$#2#
3&"
0-*
&,'-
*-2
#
!
"#$%
&'()
*+
($,
&*(-
(#.+
"/. $
(%#"
$&
..0
N
% p
# %
p #
% p
# %
p
!"#
$#"
%&'
()*
+"
8
36,4
%
28
60
,9%
20
54,1
%
21
39
,6%
+$&
,!"
%&'
()*
+"-
"
10
45,5
%
p= 0
,177
13
28
,3%
p=
0,4
03
12
32,4
%
p= 0
,995
21
39
,6%
p=
0,0
09
'),!
* "
#,!
"#'-
*-"
4 18
,2%
5 10
,9%
5 13
,5%
11
20,8
%
%
'#'0
/ 3.
04'&
,"
!
"#$%
&'()
*+
($,
&*(-
(#.+
"/. $
(%#"
$&
..0
N
% p
# %
p #
% p
# %
P
!"1
')'.
6 27
,3%
25
54,3
%
15
40
,5%
21
39,6
%
+$-
&,'0
16
72,7
%
p= 0
,057
17
37
,0%
p=
0,0
57
20
54,1
%
p= 0
,843
28
52
,8%
p=
0,4
76
.%$&
('),
!'0
0 0,
0%
4
8,7%
2 5,
4%
4
7,5%
"5
6'0
/ 1),
7*
!
"#$%
&'()
*+
($,
&*(-
(#.+
"/. $
(%#"
$&
..0
N
% p
# %
p #
% p
# %
p
!"1
')'.
8 36
,4%
12
26,1
%
8
21,6
%
10
18
,9%
+$-
&,'
11
50
,0%
p=
0,4
46
22
47,8
%
p= 0
,450
23
62
,2%
p=
0,3
94
30
56,6
%
p= 0
,204
.%$&
('),
!'
3
13,6
%
12
26
,1%
6 16
,2%
13
24,5
%
N
% p
# %
p #
% p
# %
P
!,#
*-,
!'-
*-"
!
"#$%
&'()
*+
($
,&*
(-(#
.+
"
/. $(
%#"$
& ..
0
!"#"$ 10 - !%&'"$ 3 [37]
!"!#$%&'(% !")*+'*
!"#$%&'( )*)+,-µ$.$ /&$ "'.0 $12 ."#3 45'$ (p=0,003), '$+03 '$& 6 7#'."#*,$ /&$ 1)*&--2.)*"#3 $12 ." 57$ .5.$*." (p=0,005).
85%"3, .$ '#*&2.)*$ -#µ1.0µ$.$ 1"# $7$95*"7.$& $12 .$ .*,$ .5.$*.$ .:7 $-+)707 1"# 1$*$'"%"#+";-7.$& -." <=> ),7$& 6 4#-'"%,$ -.67 $7$17"? (p=0,030), " 127"3 -.&3 $*+*0-)&3 (p=0,061) '$& 6 4#-'"%,$ -.6 -#-/'57.*:-6 /&$ ."#3 µ&-";3 $-+)7),3 (p=0,020). =1,-63, " $7?-#@"3 ;17"3 $7$95*).$& $12 ."#3 5!6 -."#3 45'$ (p=0,023), 6 %;16 /&$ ."#3 )1.( -."#3 45'$ (p=0,017) '$&6 )#)*)+&-.2.6.$ /&$ ."#3 µ&-";3 $-+)7),3 ."# <=> (p=0,010). >4&$,.)*$ $#!6µ57$ (86,50%)),7$& .$ 1"-"-.( .:7 $-+)707 1"# $759)*$7 2.& )'46%07"#7 -#µ1.0-µ$.$ $76-#@,$3-(/@"#3 (p<0,01), )70 )775$ -."#3 45'$ 46%07"#7 $4&$9"*,$ /&$ -)! (p=0,001) '$& 4#-'"%,$ -.$ -)!"#$%&'( )*)+,-µ$.$ (p=0,001). 85%"3, /&$ .$ .5--)*$ 15µ1.$, 6 7#'."#*,$ $1".)%), 57$ -6µ$7.&'2 -;µ1.:µ$ (p<0,01).
K!"#$"!$% &'()!* !+#,-'! µ( "% .(/!0()! !+"1µ("201-$%* +(3/145* +6$-& 4!1 "%+ 70!/8% 9!4:!/2;% <1!-=5"%
A7$9"*&'( µ) .67 $#."$!&"%2/6-6 .63 '&76.&'2.6-.$3, "& 1)*&."7$B'", $-+)7),3 (72,70%),'$+03 '$& $#.", ."# <=> (78,4%) $7$95*"#7 2.& $7.&µ).:1,C"#7 µ)*&'( 1*"D%?µ$.$ (p=0,035 '$& p=0,016, $7.,-."&@$), )70 1)-*&--2.)*"& $12 ."#3 µ&-";3 $&µ"'$+$&*2µ)7"#3 (56,50%) $7$95*"#7 2.& 4)7 5@"#7 '$757$ 1*2D%6µ$ '&76.&'2.6-.$3 (p<0,01). E$*(%%6%$, 6 1%)&"F69,$ .:7 4&$D6.&'07 $-+)707 (71,7%) $759)*) 2.& D&07)& µ)*&'( 1*"D%?µ$.$ '&76.&'2.6.$3 (p=0,026). G#/'*,7"7.$3 .67 &'$72.6.$ $#-.")!#16*5.6-63 µ) ." ),4"3 .63 +)*$1),$3 4)7 D*5+6-') -.$.&-.&'( -6µ$7.&'? -#-@5.&-6. A7.,+).$, 5!6 -."#3 45'$ $-+)7),3 µ) G$'@$*046 H&$D?.6 $759)*$72.& 4)7 $7.&µ).:1,C"#7 '(1"&" 1*2D%6µ$$#.")!#16*5.6-63 (p=0,005). I$.( .6 -#-@5.&-6 .63 &'$72.6.$3 .:7 $-+)-707 7$ )'.)%5-"#7 .&3 '$+6µ)*&753 ."#3 4*$-.6*&2.6.)3 µ) .67 ;1$*!6 G$'@$*046 H&$D?.6, 4&$1&-.0+6') 2.& "%&'? $7&'$72.6.$ $7.&µ).:1,C)& ." 20,8% (p=0,009). A12 .6 -.$.&-.&'? $7(%#-6 1"# 5/&7) D*5+6') 2.& 4)7 #1(*-@)& -.$.&-.&'( -6µ$7.&'? -#-@5.&-6 .63 )'.5%)-63 -#76-+&-µ57:7 4*$-.6*&".?.:7 '$& ."# ),4"#3 .63 +)*$1),$3 1"# $'"%"#+";7 "& $-+)7),3 µ) 7)9*&'? 72-". 85%"3, $12 .6 µ)%5.6 9(76') 2.& ";.) ." ),4"3 .63 +)*$1),$3 .63 7)9*&'?3 72-"#, ";.) 6 ;1$*!6 G$'@$*046 H&$D?.6 -@).,C"7.$& -6µ$7.&'( µ) ."7 127"/4#-9"*,$ ? ." (/@"3/+%,F6 (E,7$'$3 4).
>,)µ!4! 0-16"%"!* ?@5* $( $7'4/1$% µ( ;%µ-'/!314# 4!1 4,1+14# :!/!4"%/1$"14#
A7$9"*&'( µ) .67'%,µ$'$ 1"&2.6.$3 C:?3 '$& .6 -#--@5.&-? .63 µ) .67 6%&',$, D*5+6') 2.& /&$ '(+) 57$ 5."3 $;!6-63 .63 6%&',$3 "& µ"7(4)3 .63 '%,µ$'$3 1"&2.6-
.$3 C:?3 µ)&07"7.$7 '$.( 0,23 (p= 0,022). 8" 9;%" .:7 $-+)707 4)7 54)&!) 7$ )16*)(C)&, µ) -.$.&-.&'( -6µ$7.&-'2 .*21", .67 '%,µ$'$ 1"&2.6.$3 C:?3 (p=0,197). =1,-63, )70 D*5+6') 2.& /&$ '(+) 5."3 1)*&."7$B'?3 '(+$*-63 6 '%,µ$'$ 1"&2.6.$3 C:?3 µ)&07).$& '$.( 0,22 µ"7(4)3, '$& /&$ '(+) 5."3 +)*$1),$3 µ) $&µ"'(+$*-6 µ),:-6 '$.( 0,21 µ"7(4)3, .$ )#*?µ$.$ $#.( 4)7 ),7$& -.$.&-.&'( -6µ$7.&'( (p=0,335 '$& p=0,847, $7.,-."&@$). =1&1%5"7, 6 4&(*')&$ 1$*$'"%";+6-63 -." <)9*"%"/&'2 =!:.)*&'2 >$.*)," -@).,C).$& +).&'( µ) .67 '%,µ$'$ 1"&2.6.$3 C:?3, '$& -#/')'*&µ57$, /&$ '(+) 57$ @*27" 1$*$'"%";+6-63 6 '%,µ$'$ 1"&2.6.$3 C:?3 $#!(7).$& '$.( 0,758 µ) "*&-$'( -.$.&-.&'( -6µ$7.&'2 .*21" (p= 0,052). 85%"3, 4&$1&--.0+6') $-+)7?3 -#-@5.&-6 (p=0,777) µ).$!; .63 4&(*-')&$3 ."# GH '$& .63 '%,µ$'$3 1"&2.6.$3 C:?3, 46%$4? /&$ '(+) 57$ 5."3 72-"# µ) GH 6 '%,µ$'$ 1"&2.6.$3 C:?3 µ)&07).$& '$.( 0,11 µ"7(4)3.
9ABCDC9CI;*&"3 -'"123 .63 1$*";-$3 µ)%5.63 ?.$7 6 4&)-
*);76-6 ."# 9"*.,"# 72-"# .:7 $-+)707 µ) H&$D6.&'? <)9*"1(+)&$ 1*"-.)%&'"; '$& .)%&'"; -.$4,"# 7)9*&'?3 72-"#. A'2µ6, 4&)*)#7?+6') 6 1"&2.6.$ .63 C:?3 '$& 6 '$.(-.$-6 #/),$3 .:7 $-+)707 $7(%"/$ µ) ." ),4"3 .63 +)*$1),$3 1"# $'"%"#+";-$7, $%%( '$& µ) .$ '%&7&'( '$& 46µ"/*$9&'( @$*$'.6*&-.&'( ."#3.
J H< ),7$& 6 1&" '"&7? $&.,$ XNN, 1"# "46/), -) .)%&-'"; -.$4,"# 7)9*&'? 72-" '$& 1*2:*" +(7$." (Weisbord et al 2004, Phillips 2011), )70 6 -#@72.6.$ )µ9(7&-?3 .63 -#7)@,C)& 7$ $#!(7).$& 1$/'"-µ,:3 (Gagliardini et al 2015). 8$ (."µ$ µ) 7)9*&'? 72-" 1*"-.)%&'"; '$& .)-%&'"; -.$4,"#, 1"# #1"D(%%"7.$& -) KL<M, $1".)%";7 µ&$ "µ(4$ @*27&:7 $-+)707 µ) $*').( $#!6µ576 -#-7"-6*2.6.$. A12 .$ )#*?µ$.$ .63 1$*";-$3 µ)%5.63, '$& -) 1%?*6 $7.&-."&@,$ µ) .6 4&)+7? D&D%&"/*$9,$, 6 $*.6*&$'? #15*.$-6 ?.$7 $#.? 1"# ),@) .6 µ)/$%;.)*6 -#@72.6.$ (Maric & Hall 2011, Van Buren & Toto 2011), 6 $7$&µ,$ (Joss et al 2007), " G$'@$*0463 H&$D?.63, .$ '$*4&$//)&$'( 7"-?µ$.$ (Aso 2008) '$& 6 $//)&"1(+)&$ (Joseph & Friedman 2009).
N GH $1".)%), .6 -#@72.)*6 $&.,$ $10%)&$3 2*$-63 -.&3 1$*$/:/&'53 6%&',)3 -.&3 4#.&'53 @0*)3, )70 6 4&$-D6.&'? *).&7"1(+)&$, ." /%$;':µ$ '$& " '$.$**('.63, ),7$& "& -#7?+)&3 )1&1%"'53 .63 2*$-63 -."#3 4&$D6.&-'";3 $-+)7),3,µ) 1"-"-.( 1"# $//,C"#7 ." 30% (Klein & Klein 1997, ADA 2011). G.67 1$*";-$ µ)%5.6 "& $-+)7),3 µ) )1&1%"'53 .63 2*$-63, $12 "1"&$4?1".) $&.,$, (//&!$7 ." 51,5%. E$*2µ"&$ (47,2%) ),7$& '$& .$ 1"-"-.( .:7 $/-/)&"1$+),:7, 21:3 $7$95*+6'$7 $12 ."#3 ,4&"#3 ."#3 $-+)7),3. 8$ )#*?µ$.$ $12 .6 4&)+7? D&D%&"/*$9,$ $7$-95*"#7 1"-"-.2 65% .:7 )7?%&':7 4&$D6.&'07 $-+)-707 µ) .&µ53 @"%6-.)*2%63 (7: .:7 180mg/dlLDL (ADA 2014).A#.53 "& .&µ53 1*"4&$+5."#7 -) $//)&"1(+)&)3
[38] !""#$%&' (!)%'*%&' +#, $',#"!-+%&#, !(%,+#.#,
!"!#$%&'(% !")*+'*
!""# $!% &'(. )*+% ,-."./%01+2 31% 1. &'( +µ4!526+1!% µ+ ,-+78%-"#0%! 0,*53191! 01.,: 8%!;91%$.<: !-3 1.,: µ9-8%!;91%$.<: $!% µ+ -%. 0.;!7=: +-%-".$=: (Aso 2008, Thomas & Karalliedde 2015). >1. ,-3 µ+"=19 8+2/µ!, 1. =5! 1=1!71. !5!4=7+% +-+%038%. &'( $!1# 19 8%#7$+%! 19: 8%!;91%$?: 530.,.
@8%!21+79: 09µ!02!: 01.%*+2! !51"?A9$!5 !-3 1. +7B19µ!1."3/%. EuroQoL-5D-3L /%! 195 ,/+2! $!% 195 $!1#01!09 1B5 !0A+5C5 µ+ 8%!;91%$? 5+47.-#A+%! $!% *735%! 5+47%$? 530.. D $%591%$3191!, 9 !,1.+E,-97=-1909, 9 +$1="+09 1B5 0,59A%0µ=5B5 $!% $!A9µ+7%5C5 87!0197%.1?1B5, $!AC: $!% . -35.: $!% 9 8,04.72!,3--B: $!% 1. #/*.: $!% 9 A"2F9 ?1!5 .% 8%!01#0+%: 3-., .% !0A+5+2: $"?A9$!5 5! !,1.!E%."./?0.,5 195 $!1#-01!09 19: ,/+2!: 1.,:. G5!4.7%$# µ+ 195 $%591%$3191!, 130. 9 µ=A.8.: !51%µ+1C-%09: 19: 5+47%$?: 530.,, 30. $!% 9 <-!7E9 8%!;91%$?: 530.,, =8+%E!5 5! 195 +-97+-#6.,5 µ+ 01!1%01%$# 09µ!51%$3 173-.. H. 0,/$+$7%µ=5. +<79µ! =7*+1!% 0+ -"?79 0,µ4B52! µ+ 1! +,7?µ!1! 19: ;%;"%./7!42!:, 3-., 9 $%591%$3191! 8+2*5+% 5! +-97+-#6+1!% 130. !-3 19 *735%! 5+47%$? 530. $!% 19 µ=A.8. !51%µ+1C-%0?: 19: (Plantinga et al 2011, Bowling et al 2011, Fructuoso et al 2011, Brown 2012), 30. $!% !-3 195 <-!7E9 >I (Rejeski et al 2012). G-3 1! +,7?µ!1! 19: -!7.<0!: µ+"=19: 0*+1%$# µ+ 195 !,1.+E,-97=1909 $!% 195 +$1="+09 1B5 $!A9µ+7%5C5 87!0197%.1?1B5 µ35. 9 <-!7E9 8%!;91%$?: 530., (p=0,005 $!% p=0,009 !51201.%-*!) =8+%E+ 5! +-97+#6+% 09µ!51%$# 1%: 0,/$+$7%µ=5+: 8%-!01#0+%:, +<79µ! -., +-%;+;!%C5+1!% $!% !-3 -!73µ.%! µ+"=19 019 '""#8! 0*+1%$? µ+ 195 -.%3191! 6B?: 1B5 !0A+5C5 µ+ >I 1<-., 2 (Papadopoulos et al 2007).
(2! !$3µ9 09µ!51%$? -!7#µ+17.:, -., 8%+7+,5?A9-$+ $!1# 19 8%#7$+%! 19: µ+"=19:, ?1!5 . 8+2$19: 4.712-., 0,µ-1Bµ#1B5 19: *735%!: 5+47%$?: 530., $!% 19: 8%!;91%$?: 5+47.-#A+%!:. &% µ+1=*.51+: 0195 =7+,5! $"?A9$!5 5! +-%"=E.,5 !-3 =5! 0<5.". -%A!5C5 0,-µ-1Bµ#1B5 -., !5!4=7.51!% 0,*531+7! 019 8%+A5? ;%-;"%./7!42!. G-3 195 01!1%01%$? !5#",09 1B5 0,µ-1Bµ#-1B5 -., !5!4=7A9$!5, 01.,: -+7%1.5!J$.<: !0A+5+2: . =µ+1.: (p=0,034) $!% 9 $!1#A"%F9 (p=0,036) !-.1+".<5 09µ!51%$31+7! -7.;"?µ!1!. & =µ+1.: $!% 9 5!,12! !-!-51#1!% B: 0,59A%0µ=59 !51287!09 0+ !,1.<: 1.,: !0A+-5+2: (K+71#$9: 1996), +5C 9 $!1#A"%F9 =*+% 0,0*+1%01+2 0+ µ+"=1+: 130. µ+ 19 8%!;91%$? 5+47.-#A+%! /+5%$31+7! (Themeli et al 2011), 30. $!% µ+ 195 -+7%1.5!J$? $#A!709 (Yu et al 2012). >1.,: !%µ.$!A!%73µ+5.,: 1! 0,µ-1C-µ!1! -., ;7=A9$!5 B: 01!1%01%$# 09µ!51%$# !4.7.<0!5 195 !590,*2! (p=0,022), 19 "<-9 (p=0,023), 195 !8%!4.72! /%! 1. 0+E (p<0,01), 19 8,0$."2! 01! 0+E.,!"%$# +7+A2-0µ!1! (p<0,01), $!AC: $!% 19 5,$1.,72! (p<0,01). G7$+-1=: µ+"=1+: =*.,5 8+2E+% 19 0,0*=1%09 19: !590,*2!:, 19: "<-9: $!% /+5%$31+7! 1., F,*."./%$.< !512$1,-., 19: 8%!8%$!02!: 19: !%µ.$#A!709: 0195 F,*.0<5A+09 1B5
!%µ.$!A!%73µ+5B5 !0A+5C5 (Themeli et al 2011, Huwe et al 2015, Edey 2017), +5C µ+"=19 0*+1%$# µ+ 1.5 +-%--."!0µ3 1B5 0,µ-1Bµ#1B5 0+ !0A+5+2: µ+ LMM, =8+%E+ 31% =B: $!% 1. 52% 1B5 !13µB5 ;%C5+% #/*.: $!% !590,-*2! (Murtagh et al. 2007). D 0+E.,!"%$? 8,0"+%1.,7/2! -!7.,0%#6+1!% 130. 01.,: #587+: 30. $!% 01%: /,5!2$+: µ+ LMM, $!% 0*+126+1!% µ+ .7µ.5%$=: 8%!1!7!*=: -., -7.$!".<51!% !-3 19 530., !""# $!% µ+ 195 $!1#A"%F9, 19 0,5.0973191!, 195 -.",4!7µ!$2!, ? #"".,: F,*.$.%-5B5%$.<: -!7#/.51+: (Edey 2017).
>195 1+"+,1!2! .µ#8! 1B5 0,µµ+1+*351B5 019 µ+-"=19, 89"!8? 1.,: !0A+5+2: -., -!7!$.".,A.<51!5 01. 'EB1+7%$3 M+47."./%$3 @!17+2., $!1!/7#49$!5 B: 09µ!51%$# 0,µ-1Cµ!1!/-7.;"?µ!1! 9 8,0$."2! 0195 !5!-5.? (p=0,03), . -35.: 01%: !7A7C0+%: (p=0,06), 9 8,0$."2! 0,/$=517B09: (p=0,02), . !5?0,*.: <-5.: (p=0,02), 9 +,+7+A%013191! (p<0,01), 9 "<-9 (p=0,017), 9 !590,*2! (p<0,01), 9 !8%!4.72! /%! 0+E (p<0,01), 9 8,-0$."2! 01! 0+E.,!"%$# +7+A20µ!1! (p<0,01) $!% 9 5,-$1.,72! (p<0,01). D 8,0$."2! 0195 !5!-5.?, 3-B: $!% 9 #-5.%! 01.5 <-5., =*+% 0,0*+1%01+2 µ+ 1! -7C%µ! 01#8%! 19: LMM. >*+1%$# µ+ 1.5 -35. 01%: !7A7C0+%:, -., !5=-4+7!5 .% !0A+5+2: !5#"./! +,7?µ!1! !51".<51!% $!% !-3 19 8%+A5? ;%;"%./7!42!. (+"=19 19: Davison (2015), -., -7!/µ!1.-.%?A9$+ 01.5 N!5!8#, =8+%E+ 31% . -35.: -., ;%C5.,5 .% !0A+5+2: 01! -7C%µ! 01#8%! 19: 5+47%$?: 53-0., +25!% µ+/!"<1+7.: !-3 +$+25. -., ;%C5.,5 .% !%µ.-$!A!%73µ+5.% 01. 1+"%$3 01#8%. 19: 530.,. H=".:, !5!4.-7%$# µ+ 19 5,$1.,72! -., !5=4+7!5 .% !0A+5+2:, !-.1+"+2 0,59A%0µ=5. 0<µ-1Bµ! 01! -7C1! 01#8%! 19: LMM $!% 0*+126+1!% -!A.4,0%."./%$# $,72B: µ+ 195 !7197%!$? ,-=71!09 (Wu et al 2012).
>1.,: 8%!;91%$.<: !0A+5+2: 1! 0,µ-1Cµ!1! -., $!1!/7#49$!5 B: 01!1%01%$# 09µ!51%$# ?1!5 . =µ+1.: (p=0,03), .% !%µB82+: 1B5 $#1B #$7B5 (p=0,03), . -.-5.$=4!".: (p=0,03), 9 8,0$."2! 0,/$=517B09: (p=0,04) $!AC: $!% 9 8,0$."2! !51!-3$7%09: 01! 0+E.,!"%$# +7+-A20µ!1! (p<0,01). D 5!,12! $!% . =µ+1.: !-.1+".<5 0,*5# 0,µ-1Cµ!1! 19: /!017.-#7+09:, µ%!: !-3 1%: +-%-".$=: 1., >I (Cherian & Parkman 2012). & >I -7.0;#""+% 09µ!51%$# 1! 5+<7! 1B5 $#1B #$7B5 (8%!;91%$? 5+,7.--#A+%! #$7B5), µ+ !-.1="+0µ! 5! µ95 #/.51!% 0B01# 1! +7+A20µ!1! -., +25!% ,-+<A,5! /%! 19 4,0%."./%$? !2-0A909 (Mehra et al 2008). & -.5.$=4!".:, -., !5!4=7-A9$+ !-3 1.,: 0,µµ+1=*.51+:, =*+% ;7+A+2 31% 0*+126+1!% A+1%$# µ+ 1. >I (Aamodt et al 2007).>,/$+$7%µ=5!, 9 A+1%$? !,1? 0,0*=1%09 !-.828+1!% 01%: !"".%C0+%: -., -7.$!"+2 . >I 01! 1.%*Cµ!1! 1B5 !//+2B5 $!% 195 !/B-/%µ3191! 1B5 5+<7B5, 1! .-.2! !-.1+".<5 1. ,-3017Bµ! 19: 9µ%$7!52!: (Aamodt et al 2007).G5!4.7%$# µ+ 19 8,-0$."2! 0,/$=517B09: -., !5=4+7!5 .% !0A+5+2:, !-.1+-"+2 0,*53 4!%53µ+5. 1B5 8%!;91%$C5 !0A+5C5 -., 0*+-126+1!% $,72B: µ+ 1! ,-./",$!%µ%$# +-+%038%! $!AC: $!%
!"#"$ 10 - !%&'"$ 3 [39]
!"!#$%&'(% !")*+'*
µ! "#$%&%'()* +,-(+ (Katon et al 2013). ./&%0, 1 2#3)%&,+ +4-+56)7(310 3-+ 3!8%#+&()* !7!9,3µ+-+ 3-%#0 2(+:1-(-)%;0 +39!4!,0 +5%-!&!, !8+(7!-()* 3;419!0 3;µ5-<µ+, )+9=0 1 4!#7%5*9!(+ )+( 1 µ!(<µ/41 +''!(%2(+3-%&> /$%#4 <0 +5%-/&!3µ+ -1 3-#-()> 2#3&!(-%#7',+ 3-%#0 *427!0 )+( -14 )%&5()> 8176-1-+ 3-(0 '#4+,)!0 (Qiao 2003, Franconi et al 2012).
?4+@%7()* µ! -+ 21µ%'7+@()* 3-%($!,+ )+( -% 5=0 +#-* µ5%7%;4 4+ !5(27*3%#4 3-14 5%(6-1-+ A<>0 -<4 +39!4=4, +56 -1 3-+-(3-()> +4* -<4 5+7+µ/-7<4 5%# !8!-*3-1)+4 % 564%0 2!,$4!( 4+ !517!*A!-+( +56 -% @;&% (p<0,01), -%4 -65% µ64(µ10 )+-%(),+0 (p=0,012), +&&* )+( +56 -% B!,)-1 C*A+0 D=µ+-%0 (BCD) (p<0,01). E 1&(),+ <0 21µ%'7+@()6 3-%($!,% !517!*A!( -14 )(41-(-)6-1-+ (p<0,01), <0 +4+µ!46µ!4%, +&&* )+( -14 )&,µ+)+ 5%(6-1-+0 A<>0 (Rho –0,22, p=0,022). D! µ!&/-1 3! +(-µ%)+9+(76µ!4%#0 )+( 5!7(-%4+F)%;0 +39!4!,0 3-14 G&-&*2+, :7/91)! 6-( 1 /4-+31 )+( 1 3#$46-1-+ -%# 564%# +#8+46-+4 µ! -14 5*7%2% -10 1&(),+0 (Kafkia et al 2016). D! 6-( +@%7* -%4 564%, +5%-!&!, )%(46 !;71µ+, 6-( %( '#-4+,)!0 /$%#4 µ!'+&;-!71 !#+(3913,+ +56 -%#0 *4-7!0, )#7,<0 3-1 2(*7)!(+ -10 /µµ14%# 7;310, )+( +4+@/7%#4 µ! µ!'+&;-!71 3#$46-1-+ !5=2#4!0 +39/4!(!0 > 3#-µ5-=µ+-+ (Tripp et al 2006, Greenspan & Traub 2013). ?#-6, :/:+(+, ,3<0 +5%-!&!, µ1 +&19> )+-+'7+@>, )+-9=0 %( *427!0, &6'< -<4 )%(4<4()=4 )+( 5%&(-(3-()=4 5!5%(9>3!<4 5%# !5()7+-%;4 3-%4 G&&+2()6 $=7%, 2!4 +4+@/7%#4 -%4 564% 5%# :(=4%#4 '(+-, +5%-!&!, /42!(81 +2#4+µ,+0 )+( +&&%(=4!( -14 )#7,+7$1 9/31 -%#0 3-14 )%(4<4,+. C!&!-=4-+0 -1 3#3$/-(31 -%# 564%# µ! -%4 -65% 2(+µ%4>0, 5%&19>0 µ!&/-1 3-%4 H+4+2* (Tripp et al 2006) /2!(8! µ!'+&;-!7% !5(5%&+3µ6 -%# $764(%# 564%# 3! +'7%-()/0 5!7(%$/0 3! 3;')7(31 µ! -(0 +3-()/0. .%!;71µ+ +#-6 µ5%7!, 4+ +5%2%9!, ,3<0 3-% '!'%460 6-( 1 5763:+31 3-(0 #517!3,!0 #'!,+0 >-+4 &('6-!7% !;)%&1 3-(0 +'7%-()/0 5!7(%$/0 &6'< -10 µ%7@%&%',+0 -%# !2*-@%#0 )+( -<4 )&(µ+-%&%'()=4 3#491)=4. ./&%0, 1 3#-3$/-(31 -10 +;81310 -%# BCD µ! -14 +;8131 -%# 564%#, /$!( 5!7('7+@!, 3! 5%&&/0 µ!&/-!0 3-1 2(!94> :(:&(%'7+-
@,+ (Maric & Hall 2011, Stone & Broderick 2012, Yoo et al 2014, Okifuji & Hare 2015).
!"#$%&'!#'('D#µ5!7+3µ+-()*, 9+ µ5%7%;3! 4+ +4+@!79!, 6-(
-63% 1 5+7%#3,+ DB 63% )+( 1 µ/9%2%0 +4-(µ!-=5(310 -10 IJJ !517!*A%#4 3! 31µ+4-()6 :+9µ6 -14 +#-%+8(-%&6'131 -<4 +39!4=4 3-+ !5=2#4+ 3#µ5-=µ+-+ -10 463%#. G5,310 %( 5+7+5*4< 5+7*'%4-!0 !517!*A%#4 5+7+µ/-7%#0 -10 KL -<4 +39!4=4, 65<0 )(41-()6-1-+ )+( +#-%!8#517/-131.
M*41)! !5,310, 1 3#µ:%&> -10 -+)-()>0 5+7+)%&%;-91310 +56 !8!(2()!#µ/4% 4!@7%&%'()6 (+-7!,%, )+9=0 1 2(*7)!(+ 5+7+)%&%;91310 3$!-,A!-+( 9!-()* µ! -14 KL. N(+ )*9! $764% 5+7+)%&%;91310 3-% JGO 1 KL +#8*4!-+( 3-+-(3-()* 31µ+4-()*.
E /')+(71 )+( !8!(2()!#µ/41 +4-(µ!-=5(31 -<4 3#-µ5-<µ*-<4 -10 4!@7()>0 463%#, +&&* )+( 1 +5%-7%5> !µ@*4(310 > 1 )+9#3-/7131 !8/&(810 -10 BJ +5%-!-&%;4 )7(->7(+ +5+7+,-1-+ '(+ -1 2(+->7131 -10 5%(6--1-+0 A<>0 -<4 +39!4=4. E !3-,+31 -10 5%&(-!,+0 9+ 57/5!( 4+ !,4+( 57%0 -14 !4,3$#31 2%µ=4 57<-%:*9-µ(+0 @7%4-,2+0 #'!,+0 '(+ -14 /')+(71 !4-65(31 5(9+-4=4 4!@7%&%'()=4 57%:&1µ*-<4 )+( -14 5+7+5%µ5> -<4 +-6µ<4 3! !8!(2()!#µ/4+ 4!@7%&%'()> )+(/> 2(-+:1-%&%'()* )/4-7+. E 3#4!7'+3,+ -%# 3#46&%# -<4 !5+''!&µ+-(=4 #'!,+0, -63% 3-14 )%(46-1-+ 63% )+( 3-% 4%31&!#-()6 ,27#µ+, !517!*A!( 9!-()* -14 /):+31 -10 4!@7()>0 463%# )+( -%# 3+)$+7=21 2(+:>-1 µ! +5%-/-&!3µ+ )+&;-!71 57%3+7µ%'> 3-1 4/+ 57+'µ+-()6-1-+ )+( 5%(%-()6-!71 A<>.
!)µ*+,- .)//012345 E GN 3#4!(3/@!7! 3-% 3$!2(+3µ6, 3-1 3#&&%'> -<4
2!2%µ/4<4 )+( 3-1 3#''7+@> -%# )!(µ/4%#. E PH, % HH )+( 1 ?B !,$+4 -14 '!4()> !5%5-!,+ !)5641310 -10 µ!&/--10 )+( 3#4/:+&+4 !4!7'* 3-% 3$!2(+3µ6, 3-14 +8(%&6'1-31 -<4 2!2%µ/4<4 )+( 3-1 3#''7+@> -%# )!(µ/4%#. E GC 3#µµ!-!,$! 3-1 3#''7+@> -%# )!(µ/4%#.
[40] !""#$%&' (!)%'*%&' +#, $',#"!-+%&#, !(%,+#.#,
!"!#$%&'(% !")*+'*
Aamodt A.H., StovnerL.J., Midthjell K., Hagen K. & Zwart J.A. (2007). Headache prevalence related to diabetes mellitus. The Head-HUNT Study. European Journal of Neurology14(7): 738–744.
Al-Jaishi A., Oliver M., Thomas S., Lock C., Zhang J., Garg A., Kosa S., Quinn R. & Moist L. (2014). Patency rates of the arteriovenous fistula for haemodialysis: A systematic review and meta-analysis. American Journal of Kidney Disease 63: 464-478.
Almutary H., Bonner A. & Douglas C. (2013). Symptom burden in chronic kidney disease: a review of recent literature. Journal of Renal Care 39(3):140-150.
American Diabetes Association (2011). Prevention and Management of Diabetes Complications. Diabetes Care 34(Suppl. 1): S11-S61.
American Diabetes Association (2014).Standards of Medical Care in Diabetes-2014. Diabetes Care 37(Suppl.1): S14-S80.
Aso Y. (2008). Cardiovascular disease in patients with diabetic nephropathy. Current molecular medicine 8(6): 533–543.
Bowling C.B., Sawyer P., Campbell R.C., Ahmed A. & Allman R.M. (2011). Impact of chronic kidney disease on activities of daily living in community-dwelling older adults. The journals of gerontology. Biological Sciences and Medical Sciences 66(6): 689–694.
Brown E.A. (2012). What can we do to improve quality of life for the elderly chronic kidney disease patient? Aging Health 8(5): 519–524.
Cavalli A., Del Vecchio L., Anzoni C. & Locatelli F. (2010).Hemodialysis: yesterday, today and tomorrow. Minerva Urologia e Nefrologia 62(1): 1-11.
Cherian D. & Parkman H.P. (2012). Nausea and vomiting in diabetic and idiopathic gastroparesis. Neurogastroenterology and Motility 24(3): 217-222.
Davison S.N. (2015). Pain, analgesics and safety in patients with CKD.Clinical Journal of American Society of Nephrology 10, 350-352.
Edey M. (2017). Male sexual dysfunction and Chronic Kidney Disease. Frontiers in Medicine 4: 32-42
Franconi F., Campesi I., Occhioni S. & Tonolo G. (2012). Sex-gender differences in diabetes vascular complications and treatment. Endocrine, metabolic & immune disorders drug targets 12(2): 179–196.
Fructuoso M., Castro R., Oliveira L., Prata C. & Morgado T. (2011). Quality of life in chronic kidney disease. Nefrolog!a 31(1): 91–96.
Gagliardini E., Zoja C. & Benigni A. (2015). ET and Diabetic Nephropathy: Preclinical and Clinical Studies. Seminars in Nephrology 35(2): 188–196.
Greenspan J.D. & Traub R.J. (2013).Gender differences in pain and its relief. In Textbook of Pain. pp. 221–231.
Huwe N.T.T, Subramanian P., Tan L.P. & Chong W.K. (2015). The effects of acupressure on depression, anxiety and stress in patients with hemodialysis: A randomized controlled trial. International Journal of Nursing Studies 52(2): 509–518.
International Diabetes Federation (IDF).(2015). Diabetes Atlas, 7th Edition
Joseph A.J. & Friedman E.A. (2009).Diabetic Nephropathy in the Elderly.Clinics in Geriatric Medicine 25(3): 373–389.
Joss N., Patel R., Paterson K., Simpson K., Perry C. & Stirling C. (2007).Anaemia is common and predicts mortality in diabetic nephropathy. QJM: An International Journal of Medicine 100(10): 641–647.
Kafkia T., Vehvilâinen-Julkunen !. & Sapountzi KrepiaD. (2016).Assessment and managemen to fpaininrenal patients. A study of patients on Renal Replacement Therapy. Publications of the University of Eastern Finland, Kuopio. Dissertations in Health Sciences Number.
Katon W.J., Young B.A., Russo J., Lin E.H., Ciechanowski P., Ludman E.J. & van Korff M.R. (2013). Association of depression with increased risk of severe hypoglycemic episodes in patients with
diabetes. Annals of Family Medicine 11(3): 245–250.Klein R. & Klein B.E.K. (1997).Diabetic eye disease. Lancet 350(9072):
197–204.Kourakos M. (2017). Enhancing self-management in Diabetes: the
value of therapeutic education. International Journal of Health Sciences and Research 7(6): 315-321
Maric C. & Hall J.E. (2011).Obesity, Metabolic syndrome and diabetic nephropathy. Contributions to Nephrology 170: 28–35.
Mehra B.R, Thawait A.P., Karandikar S.S., Gupta D.O.& Narang R.R. (2008). Evaluation of foot problems among diabetics in rural population. Indian Journal of Surgery 70(4): 175–180.
Murtagh F.E., Addington-Hall J.& Higginson I.J.(2007).The prevalence of symptoms in end-stage renal disease: a systematic review.Advances in Chronic Kidney Disease14(1):82-99.
Okifuji A. & Hare B. (2015). The association between chronic pain and obesity. Journal of Pain Research 8: 399-408.
Phillips A.O. (2011). Diabetic nephropathy. Medicine 39(8): 470–474.Plantinga L.C., Johansen K., Crews D.C., Shahinian V.B., Robinson
B.M., Saran R., Burrows N.R., Williams D.E. & Powe N.R. for the Chronic Kidney Disease Surveillance Team (2011). Association of CKD with disability in the United States. American Journal of Kidney Diseases 57(2): 212–227.
Qiao Q. (2003). Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 26(1): 61–69.
Rejeski W.J., Edward H.I., Bertoni A.G., Bray G.A., Evans G., GreggE.W., Zhang Q. for the Look AHEAD Research Group (2012). Lifestyle Change and Mobility in Obese Adults with Type 2 Diabetes. New England Journal of Medicine 366(13): 1209–1217.
Roset M., Herdman M., Badia X. & Baro E. (2001). Uses and applications of health-related quality of life measures. The state of play in Spain. Archives of Hellenic Medicine 18(2): 131-136.
Stone A.A. & Broderick J.E. (2012). Obesity and pain are associated in the United States.Obesity 20(7): 1491–1495.
Themeli Y, Barbullushi M., Idrizi A., Bajrami V., Zaimi K., Petani E., Aliko I. & Hashorva A. .et al. (2011). Depression and diabetic nephropathy in type 2 diabetes mellitus. Asian Journal of Psychiatry 4: S90-S91.
Thomas S. & Karalliedde J. (2015).Diabetic nephropathy. Medicine 43(1):20–25.
Tripp D.A., Van Den Kerkhof E.G. & McAlister M. (2006). Prevalence and determinants of pain and pain-related disability in urban and rural settings in southeastern Ontario. Pain Research and Management 11(4): 225–233.
Unruh M.L., Weisbord S.D. & Kimmel P.L. (2005). Health-related quality of life in nephrology research and clinical practice. Seminars in Dialysis 18(2):82-90.
Van Buren P.N. & Toto R. (2011). Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management. Advances in Chronic Kidney Disease 18(1): 28–41.
Weisbord S.D., Fried L.F., Arnold R.M., Rotondi A.J., Fine M.J., Levenson D.J. & Switzer G.E. (2004). Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index. Journal of Pain and Symptom Management 27(3):226-40.
Wu A.W., Fink N.E., Marsh-Manzi J.V., Meyer K.B., Finkelstein F.O, Chapman M.M. & Powe N.P. (2004). Changes in quality of life during haemodialysis and peritoneal dialysis treatment: Generic and disease specific measures. Journal of American Society of Nephrology 15: 743-753.
Yfantopoulos J. (1998).The Greek translation and validation of the EuroQol quality of life instrument. In: Greiner W, Grafvonden Schulenburg JM, Piercy J (eds) Plenary Meeting, Discussion
"#"$#%&'()#(
!"#"$ 10 - !%&'"$ 3 [41]
!"!#$%&'(% !")*+'*
Papers, University of Hannover, Hannover:100–111.Yfantopoulos J. (2001). The Greek version of the EuroQol (EQ-5D)
instrument. Archives of Hellenic Medicine18: 180–191.Yoo J.J., Cho N.H., Lim S.H. & Kim H.A. (2014). Relationships between
body mass index, fat mass, muscle mass, and musculoskeletal pain in community residents. Arthritis & Rheumatology 66(12): 3511–3520.
Yu Z.L., Yeoh L.Y., Seow Y.Y., Luo X.C. & Griva K (2012). Evaluation of adherence and depression among patients on peritoneal dialysis. Singapore Medical Journal 53(7): 474–480.
!"#$%&#' (. & ()*)+,-./01 2. (2010). (#,3.1.) 4-56 7" 879"*"%6 µ" :;3*,) <"$;,05 8*"=/;0",): >,)$#;?6 µ".)@A 879"*B* µ" C,+3-.";) 0), (";,773.";) :;3*,) !";)="%)6. !"#$%&'()*+ 49(3):295-304.
!"#$%&#' (.(2011). (#,3.1.) D-56 0), E;3*,) *"$;,05 )*"=/;0",) ."&,0#A 7.)F%#': µ,) =#,#.,05 )*/&'71. ,)&-)#($µ".)*+ /0".(123
45&136 3(2): 70-80.G)&#+";/6 H. (2015). 2<2 101 2=?.",#6 .16 ()+037µ,)6 Iµ?;)6 <"-
$;#A. Available from: http://healthellas.gr/?author=1&paged=10. Accessed July 10, 2017.
()=)F3=#' 8.8., J,0#*#µ/016 2., G#*.#F1µ3=#' <., K;'F/6 8. & <,/0)6 >. (2007). 8@,#&3+171 .16 7E".,D3µ"*16 µ" .1* '+"%) =#,3.1.)6 D-56 F,)L1.,0B* )79"*B* .A=#' 2. 708&13 9%%$.)*+6 :3(0)*+6 24 (M'µ=. 1): 66–74.
(#&'0)*F;,B.1 N., 2')++?&#' 2., O&/E#6 :., >1µ1.;)0#=#A&#' (., G";µ"&5 (., G#'0#'&/;16 >. & G';%.71 2. (2005). (#,3.1.) D-56 )79"*B* µ" 0);0%*#. To ;+µ3 ("' 7#*%$-)"< 4(2):93-103.
P$)*.3=#' Q. (2007). N?.;171 .16 =#,3.1.)6 D-56 0), .# "';--=)R03 '+",#*#µ,03 µ#*.?&#. 708&13 9%%$.)*+6 :3(0)*+6 24 (M'µ=& 1):6-18.
K";./016 8. (1996). 2=%.#µ1 27-.";,05 ()9#&#+%), H).;,0?6 "0F37",6-()7E)&%F16, 895*).
[42] !""#$%&' (!)%'*%&' +#, $',#"!-+%&#, !(%,+#.#,
!"!#$%&'(% !")*+'*
ABSTRACT Introduction: Diabetes Mellitus (DM) is a common chronic disease accompanied by severe complications. It is the leading cause of End-Stage Renal Disease (ESRD) requiring management either by haemodialysis (HD) or peritoneal dialysis (PD). The chronicity of the disease, and its complications, affects the psychological, family and social life of the patients and their Quality of Life (QoL). Aim: of the present study was to estimate the disease burden of patients with diabetic nephropathy (DN) during pre-ESRD and during End-Stage Renal Disease. Methods: A sample of 103 patients with DN treated at the General Hospital of Veria were studied during May and June 2016. The study was conducted using the Dialysis Symptoms Index (DSI) for the assessment of Chronic Kidney Disease (CKD) symptom load and the European Quality of Life (EuroQol) questionnaire for assessing the QoL of patients in the Renal Outpatient Clinic, Haemodialysis and Peritoneal Dialysis Unit. Results: It was found that the Renal Replacement Method (HD or PD), the presence of DM and CKD’s stage affect significantly the patients’ self-assessment regarding painful symptoms of DN. Furthermore, the above factors have major impact on some aspects of patients’ QoL, such as mobility and self-care.Conclusions: Pre-End Stage patients experience more severe painful symptoms of DN compared to patients on Renal Replacement Therapies.
Key - words: Diabetes Mellitus, Disease Burden, Quality of Life, Diabetic Nephropathy, Chronic Kidney Disease
A study of the impact of disease burden in quality of life of people with pre-End-Stage and
End-Stage Renal Disease
Helen Georgiadou1, Theodora Kafkia2, Eugenia Minasidou3, Kyriakos Kazakos4,Alexandra Dimitriadou4
1. Nurse, MSc, General Hospital of Imathia-Veroia2. Clinical Lecturer, Department of Nursing, Alexander Technological Educational Institute of Thessaloniki
3. Assistant Professor, Department of Nursing, Alexander Technological Educational Institute of Thessaloniki4. Associate Professor, Department of Nursing, Alexander Technological Educational Institute of Thessaloniki
Correspondence author:Theodora KafkiaDepartment of NursingATEI of ThessalonikiPO box 14157400 Sindos, Thessalonikie-mail: dkafkia@hotmail.com
Submission Date: 10/05/2017Publication Date: October 2017
RESEARCH STUDY
HELLENIC JOURNAL OF NURSING SCIENCE 2017, 10(3): 30-42